Podcast
Oncology Overdrive
Hosted by Shikha Jain, MD · EN
In this podcast by Healio, host Shikha Jain, MD, FACP, covers modern day health care in an ever-evolving world. Through interviews with experts, Jain explores hot topics in oncology and beyond.
27episodes
Episodes
Newest firstAll episodes
Diversity and Development in Hematology with Belinda Avalos, MD
Jan 23, 202500:31:04Tap to summarizeIn this episode, host Shikha Jain, MD, speaks with ASH president, Belinda Avalos, MD, about the importance of DEI practices in medicine, leading molecular medicine developments and more. • Welcome to another exciting episode of Oncology Overdrive 0:14 • About Avalos 0:18 • The interview 1:18 • How did you know you know you wanted to be a hematologist and how did you end up in this space doing the work you’re doing now? 1:47 • Jain and Avalos on the innovations and patient relationships in the field of HemOnc that drive physician interest. 3:25 • What drove your passion to get involved in DEI and equitable care in medicine? 5:08 • Jain and Avalos on diversity in clinical trials. 7:48 • Jain and Avalos on the importance of multidisciplinary approaches to patient care. 9:08 • What do you see as the biggest barriers to driving change in this space? How can we actually make changes that will result in real-world transformation? 10:11 • Tell me about the work that you do in the spaces of women in hematology and medicine. 11:25 • What types of things should we be doing to drive gender equity changes in medicine? 13:40 • Do you feel hopeful about where we are going with the changes being driven by societies like ASH? 15:24 • What else excites you about hematology and the innovation in the field now? 17:02 • What are the biggest transformations we are going to see in hematology over the next decade? 23:26 • Where will you be focusing your time moving forward? 27:53 • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 29:16 • How to contact Avalos 30:15 • Thanks for listening 30:44 Belinda R. Avalos, MD, is the American Society of Hematology 2025 president, and is a professor of medicine and a senior advisor to the president of Atrium Health Levine Cancer. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Avalos can be reached by contacting ASH at www.hematology.org. Disclosures: Jain and Avalos report no relevant financial disclosures.
Transcribe →
The Role of Machine Learning in Clinical Trials with Damon Rasheed
Dec 30, 202400:21:11Tap to summarizeIn this episode, host Shikha Jain, MD, speaks with Opyl co-founder Damon Rasheed about using machine learning to better predict clinical trial outcomes, handling ethical concerns surrounding AI in health care and more. • Welcome to another exciting episode of Oncology Overdrive 0:14 • About Rasheed 0:20 • The interview 0:58 • How did you end up in the AI-powered medicine and clinical trials? 1:48 • What is Opyl, and what is TrialKey? 3:54 • Is TrialKey predominantly based in Australia or is it available outside of Australia as well? 5:34 • Can you explain how machine learning works in order to create these outcomes? 6:11 • How do you see people utilizing this tool in the future based on what you have already seen? 8:30 • How have others received this? What is the feedback you have gotten surrounding what people are excited and concerned about with this technology? 10:50 • Does this type of product take into account the issue of diversity in clinical trials? 13:41 • What’s next for expanding Opyl and TrialKey? 14:27 • What keeps you excited and motivated to continue working in this space? 15:28 • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 19:35 • How to contact Rasheed 20:16 • Thanks for listening 20:54 Damon Rasheed is a serial entrepreneur recognized for his groundbreaking ventures and deep expertise in machine learning and big data. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rasheed can be reached at opyl.ai or trialkey.ai. Disclosures: Jain reports no relevant financial disclosures. Rasheed reports TrialKey is powered by Opyl Limited, which is a publicly listed company operating on the ASX.
Transcribe →
Highlights from ASH 2024 (Meeting Mic Re-Release)
Dec 19, 202400:24:11Tap to summarizeIn this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the ASH Annual Meeting and Exhibition, as well as Healio’s top headlines from the meeting. Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients’ concerns as AI’s role in medicine invariably expands. :24 Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29 Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30 Read the full coverage here: AI in hematology: ‘The good, the bad and the ugly’ Mitigating financial toxicity ’better than any drug’ for people with cancer Etavopivat could offer ‘great benefit’ in sickle cell disease ASH recognizes Judith Kleinerman, MD, with Exemplary Service Award GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no financial disclosures. Abrams reports he is chair of the ASH Research Collaborative's Sickle Cell Disease Clinical Trials Network Oversight Committee. Knight reports no relevant financial disclosures. Nichols reports no relevant financial disclosures.
Transcribe →
“Back to the Future”: Developments in Immunotherapy with David Gandara, MD
Dec 12, 202400:39:30Tap to summarizeIn this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more. • Welcome to another exciting episode of Oncology Overdrive 0:14 • About Gandara 0:19 • The interview 1:02 • Can you tell me a little more about what you are working on now? 1:25 • How did you get engaged with the community in Hawaii? 6:30 • What do you think is going to happen with ctDNA moving forward? 8:29 • Can you utilize ctDNA and minimal residual disease information to determine how long patients need to be on adjuvant therapy? 11:42 • How did you get into the ctDNA space? 15:06 • How do you see AI transforming health care beyond providing patients with more information and taking more ownership of their health? 18:28 • Can you tell us more about how a second opinion clinic works? How did this type of clinic develop and become part of what you do? 23:17 • What are some of your predictions as to what will happen in oncology care over the next ten to twenty years? 29:00 • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 37:30 • How to contact Gandara 38:47 • Thanks for listening 39:10 David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug development and biomarker development. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email drgandara@ucdavis.edu. Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine.
Transcribe →
Enhancing Clinical Trial Enrollment with Michel van Harten, MD
Nov 27, 202400:25:27Tap to summarizeIn this episode, host Shikha Jain, MD, speaks with Michel van Harten, MD, about creating better information systems for physicians and patients, how shared decision-making can improve drug development and more. • Welcome to another exciting episode of Oncology Overdrive 0:14 • About van Harten 0:20 • The interview 1:00 • What was your journey to becoming a physician and beyond to where you are now? 1:24 • How did you learn the necessary skills to be an exceptional leader in this space? 2:51 • How many years were you a practicing physician for? 3:53 • What does myTomorrows do, and what drew you to this type of work? 4:54 • Where is this service available? 7:19 • Jain and van Harten on the challenges patients face surrounding eligibility for clinical trials. 8:36 • Where do you see this going down the line? 10:05 • Has your company looked into how to these services can impact diversifying clinical trial enrollment? 12:04 • What are some challenges your company has faced? 13:50 • How quickly do you think growth will accelerate in this space? 15:26 • How will this work and resource have major impacts on drug development in a more accelerated way than in the past? 16:11 • From the patient-facing side, have you faced any challenges concerning patients’ willingness to be enrolled in clinical trials? 18:22 • What is next for you, and where do you see yourself in twenty years? 19:13 • Do you have any concerns about AI in health care? […] What should we be aware of when utilizing AI in this space? 19:45 • Jain and van Harten on the challenges and setbacks that come from outdated and inaccurate clinical trial databases. 21:35 • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:50 • How to contact van Harten 24:28 • Thanks for listening 25:17 Michel van Harten, MD, is the CEO of myTomorrows. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Michel van Harten can be reached via email michel.vanharten@mytomorrows.com. Disclosures: Jain and van Harten report no relevant financial disclosures.
Transcribe →
The Data Behind Precision Medicine with Melody Harris
Nov 21, 202400:25:35Tap to summarizeIn this episode, host Shikha Jain, MD, speaks with Melody Harris about the evolution of precision medicine, what physicians and companies can do to help patients better understand precision oncology and more. • Welcome to another exciting episode of Oncology Overdrive 0:14 • About Harris 0:20 • The interview 1:11 • Tell us about how you ended up in this niche role. 1:32 • How did you make the decision to move from practicing law to transitioning your career into this space? 3:56 • Jain and Harris on the “hype” around precision medicine. 7:11 • What is the central thesis of the work at NeoGenomics? 10:36 • What do you feel companies need to be doing to make expectations surrounding diagnoses more transparent for patients? 11:49 • Where do you think this is all going in the future? Where do you think we’ll be in another ten or twenty years? 13:30 • What do you see yourself doing next? 19:04 • How can companies address the disparities in health care access, especially in underserved areas? 21:06 • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:32 • How to contact Harris 24:30 • Thanks for listening 25:14 Melody Harris serves as chief operations officer and president of informatics at NeoGenomics, a leading oncology testing services company. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Harris can be reached at melody.harris@neogenomics.com. Disclosures: Jain and Harris report no relevant financial disclosures.
Transcribe →
Highlights from 2024 World Conference on Lung Cancer (Meeting Mic Re-Release)
Nov 14, 202400:19:18Tap to summarizeIn this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the 2024 World Conference on Lung Cancer, as well as Healio’s top headlines from the meeting. With insights from Benjamin P. Levy, MD, and top headlines from the conference, Meeting Mic is your on-the-go source for highlights, pearls, and perspectives across all specialties. Benjamin P. Levy, MD, discusses key takeaways from the meeting. 0:49 Read the full coverage here: Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’ Source: Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Perioperative nivolumab improves outcomes in resectable NSCLC Source: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Despite progress, barriers to lung cancer biomarker testing persist Source: Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm relevant financial disclosures for Levy at the time of posting.
Transcribe →